Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240

AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836

α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868

A Drosophila model of Parkinson's disease

Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,156

Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders

Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046

Pathoanatomy of Parkinson’s disease

Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693

Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain

Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van der Putten, H., Probst, A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06365.2000 · Cited by 642

Neuropathology in Mice Expressing Human α-Synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06021.2000 · Cited by 563

Neuropathology in mice expressing human alpha-synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · PubMed Central · doi:10.5451/unibas-ep2767 · Cited by 505

Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease

Tanji, K., Miki, Y., Maruyama, A., Mimura, J., Matsumiya, T., Mori, F., Imaizumi, T., Itoh, K., & Wakabayashi, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.076 · Cited by 94

Synphilin-1 attenuates neuronal degeneration in the A53T -synuclein transgenic mouse model

Smith, W. W., Liu, Z. W., Liang, Y., Masuda, N., Swing, D. A., Jenkins, N. A., Copeland, N. G., Troncoso, J. C., Pletnikov, M. V., Dawson, T. M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq086 · Cited by 94

Genetic variants and animal models in SNCA and Parkinson disease

Deng, H., & Yuan, L. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.04.002 · Cited by 89

α-Synuclein Is Expressed in Different Tissues During Human Fetal Development

Baltic, S., Perović, M., Mladenović, A., Zogovic, N. S., Ruždijić, S., Rakić, L., & Kanazir, S. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:22:3:199 · Cited by 88

Models of Parkinson's disease

Orth, M., & Tabrizi, S. J. (2003) · Movement Disorders · doi:10.1002/mds.10447 · Cited by 87

Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases

Walker, D. G., & Lue, L.-F. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20484 · Cited by 89

Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background

Cabin, D. E., Gispert-Sánchez, S., Murphy, D., Auburger, G. W. J., Myers, R. R., & Nussbaum, R. L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.026 · Cited by 85

Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases

Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01020.x · Cited by 86

Relationship Among α-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra

Mori, F., Nishie, M., Kakita, A., Yoshimoto, M., Takahashi, H., & Wakabayashi, K. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000230520.47768.1a · Cited by 85

Aggregate Clearance of α-Synuclein in Saccharomyces cerevisiae Depends More on Autophagosome and Vacuole Function Than on the Proteasome

Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, M., Outeiro, T. F., & Braus, G. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.361865 · Cited by 81

Alpha-synuclein dysfunction in Lewy body diseases

Tofaris, G. K., & Spillantini, M. G. (2005) · Movement Disorders · doi:10.1002/mds.20538 · Cited by 87

Accelerated $alpha;-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells

Hasegawa, T., Matsuzaki, M., Takeda, A., Kikuchi, A., Akita, H. D., Perry, G. L., Smith, M. A., & Itoyama, Y. (2004) · Brain Research · doi:10.1016/j.brainres.2004.04.018 · Cited by 81

A calcineurin- and NFAT-dependent pathway is involved in -synuclein-induced degeneration of midbrain dopaminergic neurons

Luo, J., Sun, L., Lin, X., Liu, G., Yu, J., Parisiadou, L., Xie, C., Ding, J., & Cai, H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu377 · Cited by 79

Parkinson’s disease mouse models in translational research

Antony, P. M. A., Diederich, N. J., & Balling, R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9330-x · Cited by 84

Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of?-Synuclein inDrosophila

Pesah, Y., Burgess, H., Middlebrooks, B. W., Ronningen, K., Prosser, J., Tirunagaru, V. G., Zysk, J. R., & Mardon, G. (2005) · genesis · doi:10.1002/gene.20106 · Cited by 77

Parkinson’s disease: a rethink of rodent models

Melrose, H. L., Lincoln, S. J., Tyndall, G. M., & Farrer, M. J. (2006) · Experimental Brain Research · doi:10.1007/s00221-006-0461-3 · Cited by 74

In vivo models of alpha-synuclein transmission and propagation

Recasens, A., Ulusoy, A., Kahle, P. J., Monte, D. A. D., & Dehay, B. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2730-9 · Cited by 77

Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates

Yasuda, T., Miyachi, S., Kitagawa, R., Wada, K., Nihira, T., Ren, Y., Hirai, Y., Ageyama, N., Terao, K., Shimada, T., et al. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.052 · Cited by 72

Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia

Kawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71

Genetically engineered mouse models of Parkinson's disease

Crabtree, D., & Zhang, J. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.019 · Cited by 73

Wild-type α-synuclein interacts with pro-apoptotic proteins PKCδ and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death

Kaul, S., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.05.022 · Cited by 70

A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP

Hansen, C., Björklund, T., Petit, G. H., Lundblad, M., Nielsen, R. M., Brundin, P., & Li, J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.017 · Cited by 69

Pro‐apoptotic protein glyceraldehyde‐3‐phosphate dehydrogenase promotes the formation of Lewy body‐like inclusions

Tsuchiya, K., Tajima, H., Kuwae, T., Takeshima, T., Nakano, T., Tanaka, M., Sunaga, K., Fukuhara, Y., Nakashima, K., Ohama, E., et al. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03870.x · Cited by 68

The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain

Totterdell, S., Hanger, D. P., & Meredith, G. E. (2004) · Brain Research · doi:10.1016/j.brainres.2003.10.072 · Cited by 67

Can cellular models revolutionize drug discovery in Parkinson's disease?

Schüle, B., Pera, R. A. R., & Langston, J. W. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.014 · Cited by 64

Genetic models of Parkinson disease

Lim, K., & Ng, C.-H. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.005 · Cited by 63

Transgenic Mice with Human Mutant Genes Causing Parkinson's Disease and Amyotrophic Lateral Sclerosis Provide Common Insight into Mechanisms of Motor Neuron Selective Vulnerability to Degeneration

Martin, L. J. (2007) · Reviews in the Neurosciences · doi:10.1515/revneuro.2007.18.2.115 · Cited by 61

Are rodent models of Parkinson’s disease behaving as they should?

Vingill, S., Connor‐Robson, N., & Wade‐Martins, R. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.10.021 · Cited by 63

Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism

Fleming, S. M., & Chesselet, M. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00004 · Cited by 60

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice

Peneder, T. M., Scholze, P., Berger, M. L., Reither, H., Heinze, G., Bertl, J., Bauer, J., Richfield, E. K., Hornykiewicz, O., & Pifl, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.017 · Cited by 59

Selective noradrenergic vulnerability in alpha-synuclein transgenic mice

Sotiriou, E., Vassilatis, D. K., Vila, M., & Stefanis, L. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.11.010 · Cited by 59

Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses

Moore, D. J., Dawson, V. L., & Dawson, T. M. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:95 · Cited by 59

Convergent Pathobiologic Model of Parkinson's Disease

Maguire‐Zeiss, K. A., & Federoff, H. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07473.x · Cited by 58

Viral vectors as tools to model and treat neurodegenerative disorders

Déglon, N., & Hantraye, P. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.707 · Cited by 59

A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation

Meredith, G. E., Halliday, G. M., & Totterdell, S. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.001 · Cited by 57

Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse

Taylor, T. N., Potgieter, D., Anwar, S., Senior, S. L., Janezic, S., Threlfell, S., Ryan, B. J., Parkkinen, L., Deltheil, T., Cioroch, M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.005 · Cited by 57

Model fusion: The next phase in developing animal models for parkinson’s disease

Manning-Bog, A., & Langston, J. W. (2007) · Neurotoxicity Research · doi:10.1007/bf03033569 · Cited by 56

Synergistic effects of environmental risk factors and gene mutations in Parkinson’s disease accelerate age‐related neurodegeneration

Peng, J., Oo, M. L., & Andersen, J. K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07036.x · Cited by 54

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease

Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Fischer, D. L., Stoll, A. C., & Sortwell, C. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00621 · Cited by 56

Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor

Miller, K. M., Mercado, N. M., & Sortwell, C. E. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00179-6 · Cited by 54

Interactions between metals and α‐synuclein − function or artefact?

Brown, D. R. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05917.x · Cited by 54

α-Synuclein Elevation in Human Neurodegenerative Diseases: Experimental, Pathogenetic, and Therapeutic Implications

Ulusoy, A., & Monte, D. A. D. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8329-y · Cited by 53

Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease

Moore, D. J., & Dawson, T. M. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0045-7 · Cited by 50

The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson’s disease

Yasuda, T., & Mochizuki, H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0486-8 · Cited by 51

Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease

Bellucci, A., Navarria, L., Zaltieri, M., Missale, C., & Spano, P. (2011) · Brain Research · doi:10.1016/j.brainres.2011.11.031 · Cited by 49

Alpha Synuclein in Parkinson’s Disease

Kragh, C. L., Romero‐Ramos, M., Halliday, G. M., & Jensen, P. H. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_14 · Cited by 48

The neurological mutant quaking viable is Parkin deficient

Lorenzetti, D., Antalffy, B. A., Vogel, H. S., Noveroske, J. K., Armstrong, D. L., & Justice, M. J. (2004) · Mammalian Genome · doi:10.1007/s00335-003-2333-5 · Cited by 48

Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies

Shepherd, C. E., McCann, H., Thiel, E., & Halliday, G. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0469 · Cited by 34

Overexpression of Parkinson's disease‐associated α‐SynucleinA53T by recombinant adeno‐associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP

Dong, Z., Ferger, B., Feldon, J., & Büeler, H. (2002) · Journal of Neurobiology · doi:10.1002/neu.10094 · Cited by 47

Genetic Mouse Models of Neurodegenerative Diseases

Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 47

α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway

Prabhakaran, K., Chapman, G. D., & Gunasekar, P. G. (2011) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2011.560210 · Cited by 46

DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease

Hegde, M. L. (2009) · Frontiers in bioscience · doi:10.2741/3628 · Cited by 46

p 62 Deficiency Enhances α‐Synuclein Pathology in Mice

Tanji, K., Odagiri, S., Miki, Y., Maruyama, A., Nikaido, Y., Mimura, J., Mori, F., Warabi, E., Yanagawa, T., Ueno, S., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12214 · Cited by 46

Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse

Song, L.-K., Ma, K., Yuan, Y., Mu, Z., Song, X., Niu, F., Han, N., & Chen, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131281 · Cited by 45

Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants

Wersinger, C., & Sidhu, A. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00212-x · Cited by 45

Viral Vector Mediated Overexpression of Human α-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease

Maingay, M., Romero‐Ramos, M., & Kirik, D. (2005) · CNS Spectrums · doi:10.1017/s1092852900010075 · Cited by 45

α-Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models

Eschbach, J., & Danzer, K. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354615 · Cited by 45

Genetically engineered animal models of Parkinson's disease: From worm to rodent

Breger, L. S., & Armentero, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14300 · Cited by 45

Genetic factors involved in the pathogenesis of Parkinson's disease

Lee, F. J. S., & Liu, F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.02.001 · Cited by 43

α-Synuclein nonhuman primate models of Parkinson’s disease

Marmion, D. J., & Kordower, J. H. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1720-0 · Cited by 44

The Cast of Molecular Characters in Parkinson's Disease

LIM, K. L., Dawson, V. L., & Dawson, T. M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07465.x · Cited by 41

Influence of Different Promoters on the Expression Pattern of Mutated Human α-Synuclein in Transgenic Mice

Maskri, L., Zhu, X., Fritzen, S., Kühn, K., Ullmer, C., Engels, P., Andriske, M., Stichel, C. C., & Lübbert, H. (2004) · Neurodegenerative Diseases · doi:10.1159/000085064 · Cited by 41

Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein

Yu, W. H., Matsuoka, Y., Sziráki, I., Hashim, A., LaFrancois, J. J., Sershen, H. W., & Duff, K. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9533-4 · Cited by 41

Impairment of macroautophagy in dopamine neurons has opposing effects on parkinsonian pathology and behavior

Hunn, B. H. M., Vingill, S., Threlfell, S., Alegre-Abarrategui, J., Magdelyns, M., Deltheil, T., Bengoa-Vergniory, N., Oliver, P. L., Cioroch, M., Doig, N. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.029 · Cited by 38

Therapeutic strategies in Parkinson's disease: what we have learned from animal models

Valadas, J. S., Vos, M. H., & Verstreken, P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12577 · Cited by 44

Transgenic animal models of neurodegeneration based on human genetic studies

Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0476-6 · Cited by 38

α-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter

Pifl, C., Khorchide, M., Kattinger, A., Reither, H., Hardy, J., & Hornykiewicz, O. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.064 · Cited by 38

Mutant α‐synuclein and aging reduce neurogenesis in the acute 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine model of Parkinson’s disease

Peng, J., & Andersen, J. K. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00656.x · Cited by 37

Synucleins and their relationship to Parkinson’s disease

Halbach, O. V. B. U. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0921-7 · Cited by 37

Lifetime Proteomic Profiling of an A30P α-SynucleinDrosophilaModel of Parkinson's Disease

Xun, Z., Robinson, R. A. S., Kaufman, T. C., & Clemmer, D. E. (2007) · Journal of Proteome Research · doi:10.1021/pr0700504 · Cited by 37

Single-neuron neurodegeneration as a degenerative model for Parkinson’s disease

Huenchuguala, S., & Segura‐Aguilar, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380878 · Cited by 35

Emerging evidence for the neuroprotective role of α-synuclein

Lee, H., Zhu, X., Takeda, A., Perry, G. L., & Smith, M. A. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.04.024 · Cited by 37

Neuroproteomics as a promising tool in Parkinson’s disease research

Pienaar, I. S., Daniels, W. M. U., & Götz, J. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0070-3 · Cited by 32

Mutant genes responsible for Parkinson's disease

Le, W. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.09.005 · Cited by 31

Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease

Huang, Y., Xie, X.-X., Ji, M., Yu, X., Zhu, J., Zhang, L. L., Liu, X., Chen, W., Li, G., & Liu, R. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.024 · Cited by 30

Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?

Buchman, V. L., & Ninkina, N. N. (2008) · Neurotoxicity Research · doi:10.1007/bf03033857 · Cited by 29

Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson’s disease in young and adult mouse

Savolainen, M. H., Albert, K., Airavaara, M., & Myöhänen, T. T. (2017) · Experimental Brain Research · doi:10.1007/s00221-017-4962-z · Cited by 31

Recombinant adeno-associated virus vector design and gene expression in the mammalian brain

Paterna, J., & Büeler, H. (2002) · Methods · doi:10.1016/s1046-2023(02)00225-6 · Cited by 29

Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease

Rauschenberger, L., Behnke, J. K., Grotemeyer, A., Knörr, S., Volkmann, J., & Ip, C. W. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105798 · Cited by 29

Expression signatures of long non-coding RNA in the substantia nigra of pre-symptomatic mouse model of Parkinson's disease

Jiao, F., Wang, Q., Zhang, P., Bu, L.-L., Yan, J., & Tian, B. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.044 · Cited by 26

Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling

Kim, S. R., Ries, V., Cheng, H., Kareva, T., Oo, T. F., Yu, W. H., Duff, K., Kholodilov, N. G., & Burke, R. E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.003 · Cited by 26

Genetics of neurological disorders

Faghihi, M. A., Mottagui‐Tabar, S., & Wahlestedt, C. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.317 · Cited by 26

Mouse models of Parkinson's disease associated with mitochondrial dysfunction

Pickrell, A. M., Pinto, M., & Moraes, C. T. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.08.002 · Cited by 27

MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation

Lee, S., Oh, S. T., Jeong, H. J., Pak, S. C., Park, H., Kim, J., Cho, H., & Jeon, S. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.6.625 · Cited by 24

Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?

Lee, H., Petersen, R. B., Zhu, X., Honda, K., Aliev, G., Smith, M. A., & Perry, G. L. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00491.x · Cited by 24

Overactive Bladder Symptoms Within Nervous System: A Focus on Etiology

Qin, C., Wang, Y., & Gao, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.747144 · Cited by 23

Snca -GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological Seeding

Caputo, A., Liang, Y., Raabe, T. D., Lo, A., Horvath, M., Zhang, B., Brown, H. J., Stieber, A., & Luk, K. C. (2020) · eNeuro · doi:10.1523/eneuro.0007-20.2020 · Cited by 22

Lewy Body Disorders

Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_15 · Cited by 22

Parkinson's Disease: Genetics and Pathogenesis

Testa, C. M. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn063 · Cited by 21

Impact of fatty acid-binding proteins and dopamine receptors on α-synucleinopathy

Kawahata, K., & Fukunaga, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.12.003 · Cited by 20

Gami–Chunggan Formula Prevents Motor Dysfunction in MPTP/p-Induced and A53T α-Synuclein Overexpressed Parkinson’s Disease Mouse Model Though DJ-1 and BDNF Expression

Ahn, S., Liu, Q. F., Jang, J., Park, J., Jeong, H. J., Kim, Y., Kim, D.-H., Jeong, G., Oh, S. T., Park, S.-U., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00230 · Cited by 20

Beyond Strains: Molecular Diversity in Alpha-Synuclein at the Center of Disease Heterogeneity

Wojewska, M. J., Otero‐Jimenez, M., Guijarro-Nuez, J., & Alegre‐Abarrategui, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713199 · Cited by 19

Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician’s Perspective

Sturchio, A., Rocha, E. M., Kauffman, M., Marsili, L., Mahajan, A., Saraf, A., Vizcarra, J. A., Guo, Z., & Espay, A. J. (2024) · Brain Sciences · doi:10.3390/brainsci14020151 · Cited by 18

Mouse models as a tool for understanding neurodegenerative diseases

Ahmad‐Annuar, A., Tabrizi, S. J., & Fisher, E. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084221.82329.29 · Cited by 18

Engineered modeling and the secrets of Parkinson's disease

Vila, M., Wu, D. C., & Przedborski, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01984-6 · Cited by 18

Overexpression-Induced α-Synuclein Brain Spreading

Pinto‐Costa, R., Harbachova, E. L., Vitola, P. L., & Monte, D. A. D. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01332-6 · Cited by 17

Familial Lewy Body Diseases

Gwinn, K. A., & Singleton, A. (2002) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870201500407 · Cited by 16

Mechanisms and models of α-synuclein-related neurodegeneration

Springer, W., & Kahle, P. J. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0025-8 · Cited by 16

Role of the p62 Protein in the Formation of Neuropathological Cytoplasmic Inclusions

Kuusisto, E. (2004) · Cited by 16

Construct, Face, and Predictive Validity of Parkinson’s Disease Rodent Models

Guimarães, R. P., de Resende, M. C. S., Tavares, M. M., de Azevedo, C. V. I. B., Ruiz, M. C. M., & Mortari, M. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168971 · Cited by 18

Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice

Gómez‐Isla, T., Irizarry, M. C., Mariash, A., Cheung, B. S., Soto, O., Schrump, S. E., Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00091-x · Cited by 181

Conditional control of human wild-type and Parkinson's disease-associated mutant alpha-synuclein in transgenic mouse brain

Nuber, S., Schmidt, T., Berg, D., Neumann, M., Holzmann, C., Fendt, M., Grasshoff, U., Schmitt, I., Bornemann, A., Zimmermann, F., et al. (2004) · Aktuelle Neurologie · doi:10.1055/s-2004-833272

Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters

Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502

Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons

Daher, J. P. L., Ying, M., Banerjee, R., McDonald, R. S., Hahn, M. D., Yang, L., Beal, M. F., Thomas, B., Dawson, V. L., Dawson, T. M., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-34 · Cited by 95

Dopaminergic neuron loss and up‐regulation of chaperone protein mRNA induced by targeted over‐expression of alpha‐synuclein in mouse substantia nigra

Martin, J. L. S., Klucken, J., Outeiro, T. F., Nguyen, P. T., Keller-McGandy, C. E., Cantuti‐Castelvetri, I., Grammatopoulos, T. N., Standaert, D. G., Hyman, B. T., & McLean, P. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04310.x · Cited by 184